At the Acadia Earnings Call last week, the very first question asked by an analyst related to drug pricing in Europe and how the company was thinking about balancing pricing risk in the light of potential Most Favored Nation drug pricing.
This was Catherine Owen Adams reply
Let me maybe start with Most Favored Nation first. You know, I think as we all look out into the unknown of the future of whatever might happen with the decisions on that, we’re looking really to focus on the approval of DayBue in Europe, and then after that, as you know, reimbursement takes quite a period of time across the different member states and the countries, and we’ll assess any specific recommendations that come out of the administration with respect to, most favoured nation as we are able to sort of understand it and make decisions as we move forward on pricing and reimbursement in individual countries. With respect to EU price, I think we’ve spoken before about a number of rare analogues that are out there, that you can probably use for your modeling.
What I will say is that we are confident in getting a strong EU price that allows us to display the value that we believe we’re bringing with debut to our patients in the Rett community
Her suggestion was that analysts model European pricing of DayBue based on other comparable marketed rare disease drugs in Europe.
Reata/Biogen’s SkyClarys, has been approved in Europe and has already completed price negotiation in Germany. After statutory rebates are applied, the annual cost of SkyClarys in Germany is €320,492, equivalent to US$360,292. In comparison, the list price for SkyClarys in the US is US$370,000.
Acadia’s first entry into Europe will be in Germany, Europe’s leading pharma market.
Expand
(20min delay)